Although EGFR-TKI treatment exhibited initial beneficial effects in most patients with NSCLC, these patients eventually developed resistance to EGFR-TKIs, with disease progression within approximately a year [8, 9]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.